RxDoctor Payments Data

Donald Newman, MD

Ophthalmology · Tamaqua, PANPI 1316929482

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bausch Health US, LLC at 31.4% of the total. Reporting peaked in 2020 at $160 and has fallen 85.3% since, to $24 in 2022. That places this record below the midpoint for ophthalmology clinicians in PA, where the typical reported total is $1,202.

$327in general payments, 2019–2025

Across 13 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$102
  • GSK$75
  • Omeros Corporation$40
  • Glaukos Corporation$24
  • AbbVie$22
  • Carl Zeiss Meditec AG$19
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$30794%
  • Gifts$196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$327 in reported general payments places this provider in the 25th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$34,162
Medicare patients
195
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$20,130
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$5,453
Latanoprost104$1,624
Travoprost14$1,308
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$802
Timolol Maleate63$432
Prednisolone Acetate13$416
Dorzolamide Hcl14$365
ErythromycinErythromycin Base19$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$22$20,13046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Tamaqua

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →